Biotage AB
STO:BIOT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotage AB
Intangible Assets
Biotage AB
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Biotage AB
STO:BIOT
|
Intangible Assets
kr719m
|
CAGR 3-Years
33%
|
CAGR 5-Years
22%
|
CAGR 10-Years
19%
|
|
|
AddLife AB
STO:ALIF B
|
Intangible Assets
kr2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
BICO Group AB
STO:BICO
|
Intangible Assets
kr519.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
A
|
AroCell AB (publ)
STO:AROC
|
Intangible Assets
kr6.2m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-12%
|
|
|
G
|
Genovis AB
STO:GENO
|
Intangible Assets
kr79.3m
|
CAGR 3-Years
66%
|
CAGR 5-Years
38%
|
CAGR 10-Years
41%
|
|
|
MedCap AB (publ)
STO:MCAP
|
Intangible Assets
kr566.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
21%
|
CAGR 10-Years
13%
|
|
Biotage AB
Glance View
Biotage AB, a Swedish life sciences company, has carved a significant niche within the analytical and organic chemistry sectors since its inception. The company's core operations revolve around the development of innovative solutions designed to facilitate drug discovery, genetic research, and infection diagnostics. By offering products that simplify and accelerate chemical synthesis, Biotage has become essential to the pharmaceutical and biotechnology industries. The company's product lineup includes automated sample preparation systems, flash chromatography instruments, and peptide synthesis solutions. These tools are indispensable for researchers and lab technicians, making complex laboratory processes more efficient and less time-consuming. Financially, Biotage generates revenue through the sale and distribution of its cutting-edge laboratory instruments and their accompanying consumables. In addition to equipment sales, the company also engages in service contracts and after-sales support, which provides a steady stream of recurring income. This dual model of one-time equipment purchases combined with ongoing service and supply needs ensures a stable revenue base. Biotage stays competitive by continually innovating and refining its technology, ensuring its solutions remain indispensable to scientists addressing critical challenges in medicine, environmental testing, and other fields that demand highly precise chemical processes.
See Also
What is Biotage AB's Intangible Assets?
Intangible Assets
719m
SEK
Based on the financial report for Mar 31, 2025, Biotage AB's Intangible Assets amounts to 719m SEK.
What is Biotage AB's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
19%
Over the last year, the Intangible Assets growth was -9%. The average annual Intangible Assets growth rates for Biotage AB have been 33% over the past three years , 22% over the past five years , and 19% over the past ten years .